← board
ZYBT
distress 0/10 · well-funded / low risk$1.69+22%today-87% from 52w high
Revenue
$17M
Liquidity
$7M
Runway
—
Shares 1y
0%
Price & events
+56.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+22.5%
1D
+123.9%
1W
+116.1%
1M
+83.7%
3M
+62.1%
6M
-70.8%
1Y
—
2Y
—
5Y
-65.2%
All
Overview
- Market Cap
- $80.10M
- Enterprise Value
- $74.27M
- Volume
- 9.93M
- 52 Week Range
- $0.65 – $12.66
- Total Shares
- 47.39M
- Float Shares
- 6.26M
- Short %
- 0.10%
- % Held by Insiders
- 16.16%
- % Held by Institutions
- 1.10%
- RVOL
- 1.31x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.